Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fraser Wright

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Human Gene Therapy|April 28, 2011
New adeno-associated virus strategies to support momentum in the clinicJ Fraser Wright
Molecular Therapy. Methods & Clinical Development|March 13, 2023
AAV vector production: Troublesome host innate responses in another settingJ Fraser Wright
Methods in Molecular Biology (Clifton, N.J.)|May 19, 2011
Vector characterization methods for quality control testing of recombinant adeno-associated virusesJ Fraser Wright, Olga Zelenaia
Human Gene Therapy|December 21, 2019
Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene TherapiesRobert M Kotin, J Fraser Wright
Frontiers in Immunology|June 4, 2021
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root CausesBradley A Hamilton, J Fraser Wright
Molecular Therapy. Methods & Clinical Development|April 26, 2016
Towards routine manufacturing of gene therapy drugsOtto-Wilhelm Merten, J Fraser Wright
Nature Reviews. Endocrinology|August 29, 2024
The promising potential of gene therapy for diabetes mellitusStefan R Bornstein, J Fraser Wright, Charlotte Steenblock
Current Gene Therapy|August 18, 2010
Manufacturing and regulatory strategies for clinical AAV2-hRPE65J Fraser Wright, Jennifer Wellman, Katherine A High
Human Molecular Genetics|November 1, 2015
Progress and challenges in viral vector manufacturingJohannes C M van der Loo, J Fraser Wright
Current Opinion in Drug Discovery & Development|April 3, 2003
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vectorJ Fraser Wright, Guang Qu, Chunlin Tang, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Human Gene Therapy|April 28, 2011
New adeno-associated virus strategies to support momentum in the clinicJ Fraser Wright
Molecular Therapy. Methods & Clinical Development|March 13, 2023
AAV vector production: Troublesome host innate responses in another settingJ Fraser Wright
Methods in Molecular Biology (Clifton, N.J.)|May 19, 2011
Vector characterization methods for quality control testing of recombinant adeno-associated virusesJ Fraser Wright, Olga Zelenaia
Human Gene Therapy|December 21, 2019
Recombinant Adeno-Associated Virus Quality Control for Non-Clinical and Clinical Vectors: How an Unregulated Commercial Sector Can Compromise Development of New Gene TherapiesRobert M Kotin, J Fraser Wright
Frontiers in Immunology|June 4, 2021
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root CausesBradley A Hamilton, J Fraser Wright
Molecular Therapy. Methods & Clinical Development|April 26, 2016
Towards routine manufacturing of gene therapy drugsOtto-Wilhelm Merten, J Fraser Wright
Nature Reviews. Endocrinology|August 29, 2024
The promising potential of gene therapy for diabetes mellitusStefan R Bornstein, J Fraser Wright, Charlotte Steenblock
Current Gene Therapy|August 18, 2010
Manufacturing and regulatory strategies for clinical AAV2-hRPE65J Fraser Wright, Jennifer Wellman, Katherine A High
Human Molecular Genetics|November 1, 2015
Progress and challenges in viral vector manufacturingJohannes C M van der Loo, J Fraser Wright
Current Opinion in Drug Discovery & Development|April 3, 2003
Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vectorJ Fraser Wright, Guang Qu, Chunlin Tang, et al.
Pageof 7